Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Goodwill impairment charges (2016 - 2026)

Updated

Grace Therapeutics (GRCE) posted Goodwill impairment charges of -$13.53 million for fiscal Q1 2027 (quarter ended Jun 30, 2026).

Analysis

Grace Therapeutics (GRCE) Goodwill impairment charges (2016 - 2026) Analysis & Trends

For FY2023 (ended Mar 31, 2023), Grace Therapeutics' Goodwill impairment charges came in at -$4.83 million.

  • The fiscal Q1 2027 figure stands as the highest quarterly Goodwill impairment charges since fiscal Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.53 Mn
Sep 30, 2020 -3.71 Mn
Feb 29, 2016 339,000.00
API Access

Grace Therapeutics Goodwill impairment charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=goodwill-impairment-charges&ticker=GRCE&period=max&api_key=YOUR_API_KEY